Al's Comment:

 Each part of this combination did well in early trials, and the idea of combining them is that the oncolytic virus will create an inflammatory reaction around the tumor which would make the Car-T cells work better.  For other types of cancers, Car-t cells provided cures in a high % of patients, but so far hasn't been able to repeat that level of success in brain tumors. This combination is an attempt at the home run - bringing that success to brain tumors. 

Disclaimer: Mustang Bio is a proud sponsor of the Musella Foundation

Posted on: 04/14/2022

Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2-targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus)  


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!